Destiny Pharma PLC
LSE:DEST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Destiny Pharma PLC
Accounts Payable
Destiny Pharma PLC
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Destiny Pharma PLC
LSE:DEST
|
Accounts Payable
£768.3k
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Accounts Payable
$9.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Accounts Payable
£24.4m
|
CAGR 3-Years
28%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Accounts Payable
$15.2m
|
CAGR 3-Years
47%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Accounts Payable
£19.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-9%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Accounts Payable
£49.6m
|
CAGR 3-Years
54%
|
CAGR 5-Years
45%
|
CAGR 10-Years
30%
|
|
Destiny Pharma PLC
Glance View
Destiny Pharma Plc engages in the discovery, development and commercialization of new antimicrobial products. The company is headquartered in Brighton, Sussex. The company went IPO on 2017-09-04. The firm is engaged in the discovery, development, and commercialization of novel medicines with a focus on infection prevention. The company is focused on developing novel antimicrobial drug from its exeporfinium chloride platform and also from two biotherapeutic products. Its pipeline includes XF-73 nasal gel, NTCD-M3, and XF-73 dermal. XF-73 nasal gel is developed for the prevention of post-surgical staphylococcal infections. NTCD-M3, which is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. NTCD-M3 is used for the prevention of C. difficile infection (CDI) recurrence. XF-73 derma is developed for the prevention and treatment of serious infections associated with wounds and ulcers such as diabetic foot ulcers (DFUs). The firm is co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections.
See Also
What is Destiny Pharma PLC's Accounts Payable?
Accounts Payable
768.3k
GBP
Based on the financial report for Dec 31, 2023, Destiny Pharma PLC's Accounts Payable amounts to 768.3k GBP.
What is Destiny Pharma PLC's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-1%
Over the last year, the Accounts Payable growth was -34%. The average annual Accounts Payable growth rates for Destiny Pharma PLC have been -15% over the past three years , -1% over the past five years .
